ERBB3 and colorectal carcinoma: HER-2 is overexpressed in CRC with expression rates ranging from 2% to 11%, and both HER-2 and HER-3 are overexpressed in liver metastases of CRC patients (8% and 75%, respectively), making them promising targets for CAR-T therapies (96, 97).